Alumis Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Alumis Inc.
Former names: FL2021-001, Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: ALMS
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001847367

Board of directors

Follow this board

Alan Colowick · Director
Since 2024
David E. Goel · Director
Since 2024
James B. Tananbaum · Director
Since 2024
Lynn A. Tetrault · Director
Since 2025
Martin Babler · Director · President, CEO and Chairman
Since 2024
Patrick Machado · Director
Since 2024
Sapna Srivastava · Director
Since 2024
Srinivas Akkaraju · Director Overboarded
Since 2024
Zhengbin Yao · Director
Since 2024

Chief executives

Martin Babler · President, CEO and Chairman

Since June 2024

Director election results

Annual meeting of June 30, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

James B. Tananbaum

98.0%
Lynn A. Tetrault

99.7%

Board connections

8 of this board's directors also sit on 17 other boards. 16 are in the same sector.

Shared director Other board Same sector +1 more in the list below

Arcus Biosciences Inc. Same sector
via Patrick Machado
ArriVent BioPharma Inc. Same sector
via Zhengbin Yao
Aura Biosciences Inc. Same sector
via Sapna Srivastava
Innoviva Inc. Same sector
via Sapna Srivastava
Kalaris Therapeutics Inc. Same sector
via Srinivas Akkaraju
Latigo Biotherapeutics Inc. Same sector
via James B. Tananbaum
MapLight Therapeutics Inc. Same sector
via Martin Babler
Maze Therapeutics Inc. Same sector
via Alan Colowick
Mineralys Therapeutics Inc. Same sector
via Srinivas Akkaraju
NeoGenomics Inc.
via Lynn A. Tetrault
Neurogene Inc. Same sector
via Martin Babler
Personalis Inc. Same sector
via Alan Colowick
Prelude Therapeutics Incorporated Same sector
via Martin Babler
Rhythm Pharmaceuticals Inc. Same sector
via Lynn A. Tetrault
Scholar Rock Holding Corporation Same sector
via Srinivas Akkaraju
Xenon Pharmaceuticals Inc. Same sector
via Patrick Machado
vTv Therapeutics Inc. Same sector
via Srinivas Akkaraju

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $61,678,920; 40 purchases by 6 insiders
Sold, last 12 months: $1,572,115; 15 sales by 7 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 2, 2026	Hardiman Roy C. Officer (Chief Business & Strategy Ofcr)	Open-market sale	−652	$6.52	$4,251
Nov 2, 2026	John R. Schroer Officer (Chief Financial Officer)	Open-market sale	−794	$6.52	$5,177
Nov 2, 2026	Goldstein David M Officer (Chief Scientific Officer)	Open-market sale	−629	$6.52	$4,101
Nov 2, 2026	Drappa Jorn Officer (Chief Medical Officer)	Open-market sale	−593	$6.52	$3,866
Nov 2, 2026	Bradley Mark Christopher Officer (Chief Development Officer)	Open-market sale	−623	$6.52	$4,062
Nov 2, 2026	Pangali Sanam Officer (Chief Legal Officer)	Open-market sale	−332	$6.52	$2,165
Sep 8, 2026	Srinivas Akkaraju Director	Open-market sale	−48,066	$10.55	$507,096
Sep 8, 2026	Srinivas Akkaraju Director	Open-market sale	−48,065	$10.55	$507,086
Sep 8, 2026	Srinivas Akkaraju Director	Open-market purchase	+273,291	$10.63	$2,905,083
Sep 8, 2026	Srinivas Akkaraju Director	Open-market purchase	+273,290	$10.63	$2,905,073
Sep 4, 2026	Srinivas Akkaraju Director	Open-market purchase	+220,070	$11.17	$2,458,182
Sep 4, 2026	Srinivas Akkaraju Director	Open-market purchase	+220,070	$11.17	$2,458,182
Aug 3, 2026	Hardiman Roy C. Officer (Chief Business & Strategy Ofcr)	Open-market sale	−2,692	$26.37	$70,988
Aug 3, 2026	John R. Schroer Officer (Chief Financial Officer)	Open-market sale	−3,282	$26.37	$86,546
Aug 3, 2026	Goldstein David M Officer (Chief Scientific Officer)	Open-market sale	−2,596	$26.37	$68,457

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Alumis Inc.

Who is the CEO of Alumis Inc.?

Martin Babler has been Alumis Inc.'s President, CEO and Chairman since June 2024.

How many directors are on Alumis Inc.'s board?

Alumis Inc.'s board has 9 directors: Alan Colowick, David E. Goel, James B. Tananbaum, Lynn A. Tetrault, Martin Babler, Patrick Machado, Sapna Srivastava, Srinivas Akkaraju and Zhengbin Yao.

Are Alumis Inc. insiders buying or selling shares?

Over the last 12 months, Alumis Inc. insiders bought $61.7 million of shares in 40 purchases and sold $1.6 million of shares in 15 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Alumis Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="alumis-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.